tiprankstipranks
Advertisement
Advertisement

Exicure delays quarterly filing, trims quarterly loss

Story Highlights
  • Exicure delayed its March 2026 Form 10-Q (Quarter Report), citing extra time needed to finalize financials.
  • Preliminary results show zero revenue, a smaller net loss, and declining cash as Exicure manages costs.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Exicure delays quarterly filing, trims quarterly loss

Exicure ( (XCUR) ) has released a notification of late filing.

Claim 55% Off TipRanks

Exicure, Inc. has filed a Form 12b-25 notifying investors of a delay in submitting its Form 10-Q (Quarter Report) for the quarter ended March 31, 2026. The late filing relates specifically to the Quarterly Report on Form 10-Q (Quarter Report) covering the three-month period through that date.

The company cites the need for additional time to finalize its financial results and related disclosures as the primary reason for the delay. Management states that filing on time would require unreasonable effort or expense, but does not reference any auditor change, internal control breakdown, or special committee review.

Exicure says it expects to file the Form 10-Q (Quarter Report) within the five-day grace period allowed under SEC Rule 12b-25. That implies the report should be submitted no later than five calendar days after the original May 15, 2026 due date, assuming the review process is completed as planned.

Based on preliminary, unaudited numbers, the company expects total revenue for the quarter to be $0, unchanged from the same quarter in 2025 due to a lack of revenue-generating operations. It anticipates a narrower net loss of about $1.83 million versus roughly $3.01 million a year earlier, and cash and cash equivalents of approximately $2.50 million as of March 31, 2026, down from about $3.7 million at December 31, 2025.

Management emphasizes that these figures are preliminary and may change once the financial review is completed and the Form 10-Q (Quarter Report) is filed, underscoring their forward-looking nature. The company confirms that all other required periodic reports over the past 12 months have been filed and that it is working to remain in compliance, with the notification signed by Chief Executive Officer Jung Soo Kim on May 15, 2026.

Spark’s Take on XCUR Stock

According to Spark, TipRanks’ AI Analyst, XCUR is a Neutral.

The score is held down primarily by weak financial performance (ongoing losses, highly unstable revenue, and worsening cash burn) with only partial offset from a debt-free balance sheet. Technicals are also soft with the stock below key moving averages and a negative MACD. Corporate events are mixed—governance/legal progress and pipeline milestones help, but major leadership turnover remains a notable risk.

To see Spark’s full report on XCUR stock, click here.

More about Exicure

Exicure, Inc. is a biotechnology company that has effectively ceased revenue-generating operations and is currently incurring ongoing operating, professional, personnel-related, and working capital expenses. The firm is listed with SEC file number 001-39011 and continues to operate with limited cash resources while managing its reporting obligations as a public company.

Average Trading Volume: 18,579

Technical Sentiment Signal: Sell

Current Market Cap: $20.27M

For a thorough assessment of XCUR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1